Quantcast
Home > Quotes > ESPR
ESPR

Esperion Therapeutics, Inc. Common Stock (ESPR) Quote & Summary Data

$47.29
*  
0.10
0.21%
Get ESPR Alerts
*Delayed - data as of Sep. 18, 2018  -  Find a broker to begin trading ESPR now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ESPR After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 46 / $ 47.70
Today's High / Low
$ 47.60 / $ 45.94
Share Volume
340,901
50 Day Avg. Daily Volume
582,745
Previous Close
$ 47.19
52 Week High / Low
$ 82.68 / $ 33.06
Market Cap
1,267,545,791
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
340,901
50 Day Avg. Daily Volume:
582,745

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -6.74

Trading Range

The current last sale of $47.29 is 43.04% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 47.60 $ 82.68
 Low: $ 45.94 $ 33.06

ETFs with ESPR as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
1.61% SPDR Series Trust SPDR S&P Biotech ETF (XBI) +7.95 (9.21%)
1.16% Invesco DWA Healthcare Momentum ETF (PTH) +18.23 (23.81%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are the Lipid Management Company, a late-stage pharmaceutical company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated LDL-C. Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced lipid management team at Esperion is committed to developing new LDL-C lowering therapies that will make a substantial impact on reducing global cardiovascular disease, or CVD; the leading cause of death around the world. Bempedoic acid and our lead product candidate, the bempedoic acid / ezetimibe combination pill, are targeted therapies that have been shown to significantly reduce elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies.  ... More ...  


Risk Grade

Where does ESPR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 47
Open Date:
Sep. 18, 2018
Close Price:
$ 47.19
Close Date:
Sep. 17, 2018

Consensus Recommendation

Analyst Info